HCGUnderstand the science
How researchers evaluated hCG as a marker when an ultrasound was inconclusive
2 numbered sourcesSource years 2023, 2026
Peptides are short amino-acid chains linked by peptide bonds. Some act as messages, and related larger hormones can also serve as measurable clues to what the body is doing. Human chorionic gonadotropin (hCG) is a two-chain glycoprotein hormone produced during pregnancy. A 2026 Danish study examined what the change in naturally produced hCG could tell researchers when an early ultrasound could not locate a pregnancy. [1, 2]
A pregnancy of unknown location describes a situation in which a pregnancy test is positive, but ultrasound has yet to show where the pregnancy is developing. Several outcomes can follow, including a pregnancy inside the uterus, a pregnancy that stops developing, or an ectopic pregnancy, which develops outside the uterus. The research question was whether two blood markers could help identify people at low risk of an ectopic pregnancy within that clinical setting. [1]
Researchers enrolled 1,575 patients across multiple centers and obtained a final outcome for 1,509. They evaluated the hCG ratio, a comparison of hCG concentrations at two time points, and a progesterone measurement obtained at the initial visit. The ratio alone helped separate the outcomes but did so imperfectly. Combining the two markers improved the study's estimates of sensitivity and negative predictive value under the researchers' selected definitions. Sensitivity describes how often the approach flags people who actually have the outcome. Negative predictive value describes how often a negative result corresponds to the absence of that outcome in the group studied. [1]
The difference matters because the proportion of people who have an ectopic pregnancy affects negative predictive value. A result derived from one population, in which about eleven percent of those with final outcomes were classified as having an ectopic pregnancy or persistent pregnancy of unknown location, may behave differently elsewhere. The study evaluated risk stratification during follow-up. It did not show that blood measurements alone directly reveal the physical location of a pregnancy. The clinical outcome and imaging observations are distinct from a hormone signal measured in blood. [1]
In this study, hCG was measured as a hormone made by the body. That is a different role from the prescription products that contain hCG and are used for certain fertility indications. The 2026 evidence concerns what a change in blood concentration can contribute to assessing risk in a defined clinical population. It does not establish an outcome from treatment with hCG. [1, 2]
Sources
Original works cited in this article. Links open the external record in a new tab.
